本文選題：白蛋白結(jié)合型紫杉醇　切入點(diǎn)：復(fù)發(fā)性卵巢癌　出處：《實(shí)用婦產(chǎn)科雜志》2015年09期

【摘要】：目的:對白蛋白結(jié)合型紫杉醇(NAB-P)治療復(fù)發(fā)性卵巢癌、輸卵管癌及原發(fā)腹膜腺癌的近期療效及安全性進(jìn)行分析。方法:收集復(fù)發(fā)性卵巢癌、輸卵管癌及原發(fā)腹膜腺癌患者共21例,分析NABP為基礎(chǔ)的化療方案、治療過程中血清CA125檢測值、相關(guān)臨床及藥物不良反應(yīng)資料。采用實(shí)體瘤療效評價(jià)標(biāo)準(zhǔn)(RECIST)以及國際婦癌協(xié)會(GCIG)的CA125反應(yīng)評價(jià)標(biāo)準(zhǔn)評估療效。通過治療方案的中斷情況及患者發(fā)生的不良反應(yīng)評估以NAB-P為基礎(chǔ)方案的耐受性。結(jié)果:21例患者中,無鉑間期6個(gè)月者占33.3%(7/21),無鉑間期6個(gè)月者占66.7%(14/21)。6例患者在NAB-P基礎(chǔ)方案治療后出現(xiàn)緩解,有效率為28.6%(6/21)。CA125升高患者的有效率為33.3%(6/18),均為完全緩解。無鉑間期6個(gè)月者的有效率為42.9%(3/7),無鉑間期6個(gè)月者的有效率為21.4%(3/14),兩者比較差異無統(tǒng)計(jì)學(xué)意義(P0.05)。僅4例患者因血小板減少Ⅲ度、白細(xì)胞減少Ⅲ~Ⅳ度或中性粒細(xì)胞減少Ⅲ~Ⅳ度停止化療。結(jié)論:NAB-P為基礎(chǔ)的化療方案在接受過多線化療的卵巢癌、輸卵管癌及原發(fā)腹膜腺癌患者中有一定的臨床療效,患者的總體耐受性較好,可作為該類患者的治療選擇。
[Abstract]:Objective: to analyze the short-term efficacy and safety of albumin bound paclitaxel (NAB-P) in the treatment of recurrent ovarian cancer, fallopian tube carcinoma and primary peritoneal adenocarcinoma. Methods: 21 patients with recurrent ovarian cancer, fallopian tube carcinoma and primary peritoneal adenocarcinoma were collected. Analysis of NABP based chemotherapy regimen, serum CA125 detection value during the course of treatment, Relevant clinical and adverse drug reaction data. CA125 response evaluation criteria were used to evaluate the efficacy of solid tumor evaluation criteria (RECIST) and the International Women's Cancer Association (IGC). The tolerance of the NAB-P based scheme was evaluated. Results in 21 patients with NAB-P, The patients with no platinum interval of 6 months accounted for 33.3% and those without platinum interval for 6 months accounted for 66.7% 14 / 21.6 cases of remission after the treatment of basic NAB-P regimen. The effective rate of patients with elevated 28.6%(6/21).CA125 was 33.3 / 18%, which was completely relieved. The effective rate of patients with no platinum interval of 6 months was 42.9 / 7, and the effective rate of patients without platinum interval of 6 months was 21.440 / 3 / 14. There was no significant difference between the two groups (P 0.05). Only 4 patients had thrombocytopenia 鈪，

本文編號：1689042